Sign up USA
Proactive Investors - Run By Investors For Investors

Allergan accused of taking advantage of tribal sovereignty in patent dispute with Mylan

Allergan has transferred several patents relating to Restasis to the Native American St. Regis Mohawk Tribe
eye drops
Allergan is locked in a legal dispute with Mylan over its dry eye treatment

Drugmaker Allergan PLC (NYSE:AGN) has been taking advantage of Native American sovereignty to protect its patent for dry-eye treatment Restasis, rival Mylan Inc (NYSE:MYL) has alleged in a court filing.

Allergan on Friday said it had reached a deal to transfer several patents relating to Restasis to the Native American St. Regis Mohawk Tribe.

READ: Allergan shares move lower as second quarter losses almost double year-on-year

Mylan said in Federal District Court in Marshall, Texas, that Allergan was “attempting to misuse Native American sovereignty to shield invalid patents from cancellation”.

Allegan claims the tribe’s status as a sovereign nation means the patents for the drug would no longer be subject to review by the US Patent Trial and Appeal Board.

Generic drug companies often challenge patents before the board.

However, Allergan is not the only company to use the Regis Mohawk Tribe to shield its patents.

According to US Patent and Trademark Office records, SRC Labs LLC transferred around 40 patents to the tribe on 2 August, suggesting that such a tactic could be used by companies beyond the pharmaceutical sector.

Shares in Allergan edged down 0.48% to US$230.26 in afternoon trading.

View full AGN profile View Profile

Allergan Timeline

Newswire
February 08 2017
Newswire
December 20 2016
Newswire
November 02 2016
Article
September 20 2016

Related Articles

pregnant woman sitting in park
June 13 2017
The £225,000 order is from HuanZhong Biotech, Concepta’s partner in China
the word antioxidant
August 15 2017
The heparin test is the firm’s lead product; however the company’s OxiChek device for oxidative stress is also gaining traction
1504120610_biotechLatest.jpg
August 31 2017
The company is poised for a milestone-rich period over the next year or so
Copyright © Proactiveinvestors.com, 2017. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use